Patient Grand Rounds Example

In this insightful grand rounds example, Carevive focuses on a 76-year-old female patient diagnosed with stage four non-small cell lung cancer, with evidence of brain metastases. The patient’s biomarker status indicates PDL-1 positivity, and she also has a history of diabetes. While the patient continues to work part-time and leads an active lifestyle, she faces the challenges of living alone.

The treatment history reveals a course of immunotherapy, including nivolumab and ipilimumab, followed by pembrolizumab with carboplatin and paclitaxel. Carevive then provides an in-depth analysis of the patient’s symptom burden and treatment bother over the treatment timeline.

Symptom reporting spikes correlate with the treatment course, with certain symptoms standing out as severe, such as decreased appetite, fatigue, and muscle pain. The granular data on symptom interference with daily life highlights fatigue and muscle pain as persistent challenges throughout treatment.

Carevive’s detailed insights go beyond symptom burden, shedding light on the patient’s functional status over time. The patient’s ability to tolerate the multimodal therapy is evident from the maintained moderate function and treatment bother levels.

Through this case study, Carevive demonstrates the power of personalized data-driven insights. Understanding individual patient experiences empowers care teams to tailor support, leading to better treatment decisions, symptom management, and ultimately improved patient outcomes.

Carevive’s commitment to patient-centered care continues to revolutionize oncology treatment, providing clinicians with valuable tools to optimize patient care and well-being. With data-driven insights and a focus on patient quality of life, Carevive sets a new standard in patient care and support.

Recent Episodes

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…